Media stories about Champions Oncology (NASDAQ:CSBR) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Champions Oncology earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.6520074607206 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Champions Oncology (NASDAQ:CSBR) traded up $0.17 during mid-day trading on Tuesday, reaching $3.76. 119,300 shares of the company were exchanged, compared to its average volume of 52,957. Champions Oncology has a 12 month low of $2.09 and a 12 month high of $4.79.

Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings results on Thursday, September 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. Champions Oncology had a negative return on equity of 338.01% and a negative net margin of 29.87%. The company had revenue of $5.03 million during the quarter.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Champions Oncology (CSBR) Share Price” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://theolympiareport.com/2017/12/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-champions-oncology-csbr-share-price.html.

About Champions Oncology

Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.